Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik

Oncogene

Volumn 24, Issue 49, 2005, Pages 7369-7380

  Oppermann, Malte ^a   Geilen, Christoph C ^a   Fecker, Lothar F ^a   Gillissen, Bernhard ^a   Daniel, Peter T ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; BH3 only; Melanoma; Nbk Bik

Indexed keywords

ANTINEOPLASTIC AGENT; BCL 2 INTERACTING KILLER PROTEIN; CASPASE; CYTOCHROME C; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; MESSENGER RNA; NATURAL BORN KILLER PROTEIN; PAMIDRONIC ACID; PROTEIN; PROTEIN BCL 2; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CHROMATIN CONDENSATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CHROMATIN; CYTOCHROMES C; DIPHOSPHONATES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; INJECTIONS, SUBCUTANEOUS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; TETRACYCLINE; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 27744535981     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208890     Document Type: Article

References (52)

1. Bang B, Baadsgaard O, Skov L and Jaattela M. (2004). Arch. Dermatol. Res., 296, 67-73.
2. Borner C. (2003). Mol. Immunol., 39, 615-647.
3. Bouillet P, Cory S, Zhang LC, Strasser A and Adams JM. (2001). Dev. Cell, 1, 645-653.
4. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ and Chinnadurai G. (1995). Oncogene, 11, 1921-1928.
5. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA and Giaccone G. (2004). Cancer Res., 64, 27-30.
6. Bruggen J, Fogh J and Sorg C. (1981). J. Cancer Res. Clin. Oncol., 102, 141-152.
7. Carey TE, Takahashi T, Resnick LA, Oettgen HF and Old LJ. (1976). Proc. Natl. Acad. Sci. USA, 73, 3278-3282.
8. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM and Strasser A. (2004). Mol. Cell. Biol., 24, 1570-1581.
9. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B and Brown R. (1999). Blood, 94, 1100-1107.
10. Daniel PT, Schulze-Osthoff K, Belka C and Guner D. (2003). Essays Biochem., 39, 73-88.
11. Eberle J, Fecker LF, Bittner JU, Orfanos CE and Geilen CC. (2002). Br. J. Cancer, 86, 1957-1962.
12. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE and Geilen CC. (2003). Oncogene, 22, 9131-9141.
13. Eberle J, Weitmann S, Thieck O, Pech H, Paul M and Orfanos CE. (1999). J. Invest. Dermatol., 112, 925-932.
14. Eisinger M and Marko O. (1982). Proc. Natl. Acad. Sci. USA, 79, 2018-2022.
15. Elangovan B and Chinnadurai G. (1997). J. Biol. Chem., 272, 24494-24498.
16. Fecker LF, Geilen CC, Hossini AM, Schwarz C, Fechner H, Bartlett DL, Orfanos CE and Eberle J. (2005). J. Invest. Dermatol., 124, 221-228.
17. Festjens N, van Gurp M, van Loo G, Saelens X and Vandenabeele P. (2004). Acta Haematol., 111, 7-27.
18. Fischer U, Janicke RU and Schulze-Osthoff K. (2003). Cell Death Differ., 10, 76-100.
19. Fischer U and Schulze-Osthoff K. (2005). Cell Death Differ. (in press).
20. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, Elling F, Leist M and Jaattela M. (2001). J. Cell Biol., 153, 999-1010.
21. Garbe C and Blum A. (2001). Skin Pharmacol. Appl. Skin Physiol., 14, 280-290.
22. Germain M, Mathai JP and Shore GC. (2002). J. Biol. Chem., 277, 18053-18060.
23. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B, Schulze-Osthoff K and Daniel PT. (2003). EMBO J., 22, 3580-3590.
24. Gossen M and Bujard H. (1992). Proc. Natl. Acad. Sci. USA, 89, 5547-5551.
25. Guner D, Belka C and Daniel PT. (2003). Curr. Med. Chem. Anti-Cancer Agents, 3, 319-326.
26. Han J, Sabbatini P and White E. (1996). Mol. Cell. Biol., 16, 5857-5864.
27. Hossini AM, Eberle J, Fecker LF, Orfanos CE and Geilen CC. (2003). FEBS Lett., 553, 250-256.
28. Hur JY, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ and Shioda T. (2004). Proc. Natl. Acad. Sci. USA, 101, 2351-2356.
29. Hussein MR, Haemel AK and Wood GS. (2003). J. Pathol., 199, 275-288.
30. Igney FH and Krammer PH. (2002). Nat. Rev. Cancer, 2, 277-288.
31. Jiang AM and Clark EA. (2001). J. Immunol., 166, 6025-6033.
32. Juin P, Geneste O, Raimbaud E and Hickman JA. (2004). Biochim. Biophys. Acta, 1644, 251-260.
33. Lockshin A, Giovanella BC, De Ipolyi PD, Williams Jr LJ, Mendoza JT, Yim SO and Stehlin Jr JS. (1985). Cancer Res., 45, 345-350.
34. Mathai JP, Germain M, Marcellus RC and Shore GC. (2002). Oncogene, 21, 2534-2544.
35. Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P and Weller M. (2003). Hum. Gene Ther., 14, 1235-1246.
36. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C. (1991). J. Immunol. Methods, 139, 271-279.
37. Orth R and Dixit VM. (1997). J. Biol. Chem., 272, 8841-8844.
38. Paquet C, Schmitt E, Beauchemin M and Bertrand R. (2004). Apoptosis, 9, 815-831.
39. Radetzki S, Kohne CH, von Haefen C, Gillissen B, Strum I, Dorken B and Daniel PT. (2002). Oncogene, 21, 227-238.
40. Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE and Geilen CC. (2000). FEBS Lett., 473, 27-32.
41. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC. (2001). J. Invest. Dermatol., 117, 333-340.
42. Reed JC, Doctor KS and Godzik A. (2004). Sci. STKE, 2004, re9.
43. Riedl SJ and Shi Y. (2004). Nat. Rev. Mol. Cell Biol., 5, 897-907.
44. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B and Daniel PT. (2005). Oncogene, 24, 1904-1913.
45. Schotte P, Declercq W, Van Huffel S, Vandenabeele P and Beyaert R. (1999). FEBS Lett., 442, 117-121.
46. Soengas MS and Lowe SW. (2003). Oncogene, 22, 3138-3151.
47. Suzuki M, Hisamatsu T and Podolsky DK. (2003). Infect. Immunol., 71, 3503-3511.
48. Theodorakis P, Lomonosova E and Chinnadurai G. (2002). Cancer Res., 62, 3373-3376.
49. Tong Y, Yang Q, Vater C, Venkatesh LK, Custeau D, Chittenden T, Chinnadurai G and Gourdeau H. (2001). Mol. Cancer Therapeut., 1, 95-102.
50. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P. (2002). Cell Death Differ., 9, 1031-1042.
51. Verma S, Zhao LJ and Chinnadurai G. (2001). J. Biol. Chem., 276, 4671-4676.
52. Wieder T, Orfanos CE and Geilen CC. (1998). J. Biol. Chem., 273, 11025-11031.